insights_auto
Why is TWST down 15.54%?
Dive Deeperchevron_right
TWST:NASDAQ
Twist Bioscience Corp
$129.04
arrow_downward
-15.54%(-23.74) 1D
$128.49
arrow_downward
-0.43% (-0.55)bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TWST...
Open
$153.17
High
$154.22
Low
$128.29
Mkt. cap
8.55B
Avg. vol.
2.94M
Volume
2.67M
52-wk high
$219.71
52-wk low
$23.30
EPS
-$2.22
Beta
2.19
Shares outstanding
65.83M
No. of employees
979
Open
$153.17
High
$154.22
Low
$128.29
Mkt. cap
8.55B
Avg. vol.
2.94M
Volume
2.67M
52-wk high
$219.71
52-wk low
$23.30
EPS
-$2.22
Beta
2.19
Shares outstanding
65.83M
No. of employees
979
News stories
From web sources and news partners
Foreign Policy Journal
·
35 minutes ago
RTX Corporation's (NYSE: RTX) $271 Billion Backlog Fuels Analyst Optimism Despite Engine Concerns
Dealroom
·
39 minutes ago
Agility Robotics clears SPAC vote, expects $465M and Nasdaq debut November 5
investingLive
·
8 minutes ago
JPMorgan’s four midterm scenarios: S&P 500 seen moving between -0.25% and +1.25%
Bloomberg.com
·
4 hours ago
Nasdaq 100 Enters Correction as Megacap Results Amplify AI Fears
Profile
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
About Twist Bioscience Corp
Analyst ratings
Based on 11 analysts giving stock ratings to TWST in the past 3 months
Buy
Buy
8
Hold
2
Sell
1
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for TWST in the last 3 months.
Highest
Current $129.04
$215.00 (+66.62%)
Average
$158.10 (+22.52%)
Lowest
$45.00 (-65.13%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Brendan Smith TD Cowen | Buy | Reiterated | $190.00 | +47.2% | 10/13/2026 |
Kyle Mikson CFA Canaccord Genuity | Buy | Maintained | $205.00 | +58.9% | 10/12/2026 |
Matthew Stanton, CFA Jefferies | Hold | Initiated | $150.00 | +16.2% | 10/07/2026 |
Luke Sergott Barclays | Buy | Maintained | $215.00 | +66.6% | 10/07/2026 |
Subbu Nambi Guggenheim | Buy | Maintained | $212.00 | +64.3% | 10/01/2026 |
Puneet Souda Leerink Partners | Buy | Maintained | $190.00 | +47.2% | 09/29/2026 |
Hamed Khorsand BWS Financial | Sell | Maintained | $45.00 | -65.1% | 09/18/2026 |
Unknown Analyst UBS | Hold | Initiated | $144.00 | +11.6% | 09/08/2026 |
Doug Schenkel UBS | Hold | Initiated | $144.00 | +11.6% | 09/09/2026 |
David Westenberg Piper Sandler | Buy | Reiterated | $115.00 | -10.9% | 08/05/2026 |
Catherine Ramsey Schulte Robert W. Baird | Buy | Maintained | $115.00 | -10.9% | 08/04/2026 |
Matt Larew William Blair | Buy | Reiterated | - | - | 08/03/2026 |
Vijay Kumar Evercore ISI | Hold | Downgraded | $102.00 | -21% | 07/06/2026 |
Next call in 9 days
Thu, Nov 12, 8:00 AM
Fiscal period
Q4 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$0.20
Revenue / Est. (USD)
- / 123.58M
Fiscal Q4 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 99.01M | 103.70M | 110.72M | 118.38M |
Cost of goods sold | 48.17M | 49.73M | 53.59M | 55.92M |
Cost of revenue | 48.17M | 49.73M | 53.59M | 55.92M |
Research and development expenses | 17.01M | 17.13M | 19.70M | 18.02M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 63.76M | 69.74M | 76.08M | 80.71M |
Operating expense | 80.77M | 86.87M | 95.78M | 98.73M |
Total operating expenses | 128.94M | 136.60M | 149.37M | 154.66M |
Operating income | -29.93M | -32.90M | -38.66M | -36.28M |
Other non operating income | 420.00K | 471.00K | 175.00K | 40.00K |
EBT including unusual items | -26.88M | -30.25M | -43.98M | -34.74M |
EBT excluding unusual items | -26.88M | -30.25M | -36.77M | -34.74M |
Income tax expense | 257.00K | 253.00K | 43.00K | 311.00K |
Effective tax rate | -0.96% | -0.84% | -0.10% | -0.90% |
Other operating expenses | - | - | - | - |
Net income | -27.14M | -30.51M | -44.02M | -35.05M |
Net profit margin | -27.41% | -29.42% | -39.76% | -29.61% |
Earnings per share | -0.45 | -0.50 | -0.60 | -0.56 |
Interest and investment income | 2.63M | 2.18M | 1.71M | 1.50M |
Interest expense | - | - | - | - |
Net interest expenses | 2.63M | 2.18M | 1.71M | 1.50M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -26.03M | -27.01M | -32.44M | -29.80M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events